Trevi Therapeutics, Inc. (TRVI)
NASDAQ: TRVI · Real-Time Price · USD
6.50
-0.03 (-0.38%)
At close: Mar 28, 2025, 4:00 PM
6.45
-0.05 (-0.77%)
After-hours: Mar 28, 2025, 7:27 PM EDT
Trevi Therapeutics Employees
Trevi Therapeutics had 26 employees as of December 31, 2024. The number of employees increased by 1 or 4.00% compared to the previous year.
Employees
26
Change (1Y)
1
Growth (1Y)
4.00%
Revenue / Employee
n/a
Profits / Employee
-$1,842,731
Market Cap
628.43M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TRVI News
- 12 days ago - Trevi Therapeutics, Inc. (TRVI) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates - PRNewsWire
- 19 days ago - Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 - PRNewsWire
- 20 days ago - Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps - Benzinga
- 20 days ago - Trevi Therapeutics Announces Positive Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough - PRNewsWire
- 21 days ago - Trevi Therapeutics to Host Conference Call and Webcast on March 10th to Share Topline Results from the Phase 2a RIVER Trial of Haduvio in Patients with Refractory Chronic Cough - PRNewsWire
- 4 weeks ago - Trevi Therapeutics to Participate in Upcoming March Investor Conferences - PRNewsWire
- 4 weeks ago - Trevi Therapeutics Completes Enrollment for Phase 2b CORAL Trial of Haduvio in Idiopathic Pulmonary Fibrosis Patients with Chronic Cough - PRNewsWire